Actinogen Medical Limited
ATGGF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$178.21M
Close$
$0.00
91.5% downside
Current Fair Value
91.5% downsideOvervalued by 91.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $178.21 Million |
|---|---|
| Enterprise Value | $166.26 Million |
| Earnings per Share | $0 |
| Beta | 0.89 |
| Outstanding Shares | 3,302,712,647 |
Return
| Return on Equity | -140.88% |
|---|---|
| Return on Assets | -101.88% |
| Return on Invested Capital | -202.54% |
Valuation & Multiples
| P/E Ratio | -9.58 |
|---|---|
| PEG | 24.86 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 30.29 |
| Enterprise Value to EBIT | -3.82 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
February 24, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Actinogen Medical Limited
6 employees
CEO: Steven G. Gourlay
Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of ...